Back Back
CAR T Bridging for MM: Module

CME

The Role of Bridging Therapeutic Strategies for Patients With Multiple Myeloma Receiving CAR T-Cell Therapy

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit™

Released: July 17, 2023

Expiration: July 16, 2024

Thomas G. Martin
Thomas G. Martin, MD
CME/CE Information

Activity

Progress
1
Course Completed

Introduction

In this module, Thomas G. Martin, MD, describes current roles of autologous CAR T cell therapy in multiple myeloma (MM) with a focus on bridging therapy. First, he reviews the basics of CAR T-cell therapy for MM, including landmark clinical data and safety, and then shares his current real-world experience with standard-of-care (SoC) CAR T-cell therapy. Next, he discusses the potential for CAR T-cell therapy in earlier lines of treatment, and finally he reviews alternative therapies for MM, including bispecific antibodies and next-generation cereblon E3 ligase (CEL) modulators.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. Some questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

For those providing patient care, how many patients with MM do you provide care for in a typical month?

Which of the following is not a goal of bridging therapeutic strategies prior to CAR T-cell therapy in the real-world treatment of patients with MM?

Which of the following factors in a patient with relapsed/refractory (R/R) MM is least indicative of a need for bridging therapy while awaiting a CAR T-cell manufacturing slot?

Which of the following treatment regimens would be best to avoid as a bridging therapy for a patient with R/R MM awaiting a CAR T-cell manufacturing slot?

BACK | NEXT